Xencor, Inc. (NASDAQ:XNCR) is reporting third quarter financial results on Thursday 5th November 2020, after market close.
According to analysts surveyed by Thomson Reuters, XNCR is expected to report 3Q20 loss of $ 0.23 per share from revenue of $ 33.44 million.
For the full year, analysts anticipate top line of $ 94.49 million, while looking forward to loss of $ 1.57 per share bottom line.
Previous Quarter Performance
Xencor, Inc. recorded loss for the second quarter of $ 0.61 per share, from the revenue of $ 13.09 million. The quarterly revenues declined 32.84 percent compared with the same quarter last year. The consensus estimates are loss of $ 0.50 per share from $ 12.61 million in revenue. The bottom line results missed street analysts by $ 0.11 or 22 percent, at the same time, top line results outshined analysts by $ 0.48 million or 3.81 percent.
Stock Performance
Shares of Xencor, Inc. traded up $ 1.86 or 4.69 percent on Wednesday, reaching $ 41.50 with volume of 243.50 thousand shares. Xencor, Inc. has traded high as $ 42.74 and has cracked $ 39.44 on the downward trend
The closing price of $ 41.50, representing a 104.86 % increase from the 52 week low of $ 19.35 and a 9.7 % decrease over the 52 week high of $ 43.90.
The company has a market capital of $ 2.38 billion and is part of the Healthcare sector and Biotechnology industry.
Recent Analyst recommendations
- On 8th September 2020, maintained by SVB Leerink at Outperform rating, with $ 39.00 target price.
Conference Call
Xencor, Inc. will be hosting a conference call at 4:30 PM eastern time on 5th November 2020, to discuss its 3Q20 financial results with the investment community. A live webcast with presentations will be available on the Internet by visiting the Company website www.xencor.com
Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat autoimmune and allergic diseases, cancer, and other conditions. The companys product candidates include XmAb5871, an immune inhibitor, which has been completed Phase II clinical trial for the treatment of autoimmune diseases; and XmAb7195, an immune inhibitor that has been completed Phase I clinical trial for the treatment of asthma and allergic diseases.
